Clinical trial
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
NCT00076843 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00076843 |
|---|---|
| Title | Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis |
| Official title | Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HTLV-1 |
| Intervention type | Drug |
| Interventions | Hu MiK-Beta-1 |
| Enrollment | 9 |
| Start date | Feb 3, 2004 |
| Primary completion | Oct 11, 2017 |
| Completion | Jun 25, 2019 |
| First posted | Feb 4, 2004 |
| Last update posted | Jun 27, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: